# Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

> **NCT02194400** · PHASE1 · COMPLETED · sponsor: **Resolve Therapeutics** · enrollment: 32 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** RSLV-132

## Key facts

- **NCT ID:** NCT02194400
- **Lead sponsor:** Resolve Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194400, "Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02194400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*